Guardant Health, Inc. (GH) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Diagnostics & Research 산업에서 운영. 본사 소재지는 Palo Alto, CA, 미국. 현재 CEO는 Helmy Eltoukhy.
GH 을(를) 보유 IPO 날짜 2018-10-04, 1,999 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $11.33B.
Guardant Health, Inc. is a precision oncology company that develops and provides innovative blood-based liquid biopsy tests and analytics for cancer detection and treatment. The company offers a portfolio of products including Guardant360 and its variants for advanced-stage cancer patients, GuardantINFORM for clinical genomic research, and LUNAR-2 for early colorectal cancer detection, as well as GuardantConnect, a software platform connecting patients with relevant clinical trials. Additionally, Guardant Health provides development services to biopharmaceutical companies and medical institutions, including companion diagnostic development, clinical trial support, and testing solutions. Headquartered in Redwood City, California, the company operates globally and serves the oncology market through its comprehensive suite of diagnostic and data analytics offerings.
